Inventiva's MASH and T2D Study Accepted As Late-Breaker At AASLD 2024

Inventiva is a clinical-stage biopharmaceutical company chiefly developing oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). It has announced that the results from its Phase 2 LEGEND study have been accepted as a late-breaking presentation at the 75th Annual American Association for the Study of Liver Diseases (AASLD) Liver Meeting® 2024. The study evaluated lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The conference will be held from November 15 to 19, 2024, in San Diego, California. 

The poster presentation details are as follows:

Abstract Title - Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D). 

Publication Number - 5040.

The Poster Will Be Presented By - Michelle Lai, Onno Holleboom, Lucile Dzen, Philippe Huot-Marchand, Jean-Louis Junien, Pierre Broqua, Louis Griffel, Sanjay Patel, and Michael P Cooreman. 

Date & Time - Monday, November 18th, 8:00 AM-5:00 PM PST